









Markets
/
Stocks
/
nasdaq-thtx
/

Theratechnologies Inc

THTX

3.300USD

-0.010-0.30%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

151.73MMarket Cap

LossP/E TTM



Theratechnologies Inc

3.300

-0.010-0.30%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

98 / 175

Overall Ranking

320 / 4720

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

3.800

Target Price

+14.80%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

Growing

The company is in a growing phase, with the latest annual income totaling USD 85.87M.

Undervalued

The company’s latest PE is -17.79, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 22.32M shares, decreasing 4.58% quarter-over-quarter.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.45.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 6.75, which is lower than the Pharmaceuticals industry's average of 7.84. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 17.73M, representing a year-over-year decrease of 19.48%, while its net profit experienced a year-over-year decrease of 552.08%.

Score

Industry at a Glance

Previous score

6.75

Change



Financials

5.96

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

4.91

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.67

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.21

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is -17.84, which is -89.14% below the recent high of -1.94 and 39.25% above the recent low of -10.84.

Score

Industry at a Glance

Previous score

1.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 98/175

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.00, which is lower than the Pharmaceuticals industry's average of 7.78. The average price target for Theratechnologies Inc is 3.80, with a high of 3.80 and a low of 3.80.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

3.800

Target Price

+14.80%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Theratechnologies Inc

THTX

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 4.78, which is lower than the Pharmaceuticals industry's average of 6.84. Sideways: Currently, the stock price is trading between the resistance level at 3.35 and the support level at 3.25, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.78

Change

-0.28

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.006

Neutral

RSI(14)

69.590

Neutral

STOCH(KDJ)(9,3,3)

61.275

Sell

ATR(14)

0.023

High Vlolatility

CCI(14)

87.607

Neutral

Williams %R

36.842

Buy

TRIX(12,20)

0.125

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

3.301

Sell

MA10

3.290

Buy

MA20

3.269

Buy

MA50

3.216

Buy

MA100

2.928

Buy

MA200

2.335

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Investissement Québec

9.12M

Soleus Capital Management, L.P.

4.80M

-0.00%

Nantahala Capital Management, LLC

2.42M

-9.68%

AIGH Capital Management, LLC.

1.75M

-23.48%

Morgan Stanley & Co. LLC

2.21M

-2.61%

Worth Venture Partners, LLC

576.93K

-22.04%

National Bank of Canada

197.07K

+2.57%

Molson (Andrew Thomas)

137.50K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 4.85, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.76. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.